It’s a very difficult situation at this moment because many of the luminal type breast cancer can have a better prognosis in general by conventional treatment. So for avoiding the additional toxicity, so we need to think about how to titrate the patient population. And also there are other drugs such as CDK4/6 inhibitors coming next generation or third. So this kind of thing, this kind of drug can get a more preferable prognosis for such kind of patients...
It’s a very difficult situation at this moment because many of the luminal type breast cancer can have a better prognosis in general by conventional treatment. So for avoiding the additional toxicity, so we need to think about how to titrate the patient population. And also there are other drugs such as CDK4/6 inhibitors coming next generation or third. So this kind of thing, this kind of drug can get a more preferable prognosis for such kind of patients. So the combination of endocrinotherapy, targeting agent, MTOR inhibitor, probably patients may have more benefit than before.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.